MannKind told analysts yesterday afternoon that it has opened up discussions with a few more potential commercial partners for Afrezza, an inhaled insulin product that is waiting on a final ruling from the FDA. The agency delayed its decision on the fast-acting insulin--which has attracted a big crowd of skeptics and true believers--in the middle of January, saying that it had not completed an inspection of a third-party manufacturing site. Report